Stock Research for ADRU

ADRU

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ADRU Stock Chart & Research Data

The ADRU chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ADRU chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ADRU Due diligence Resources & Stock Charts

The ADRU stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ADRU Detailed Price Forecast - CNN Money CNN View ADRU Detailed Summary - Google Finance
Yahoo View ADRU Detailed Summary - Yahoo! Finance Zacks View ADRU Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ADRU Trends & Analysis - Trade-Ideas Barrons View ADRU Major Holders - Barrons
NASDAQ View ADRU Call Transcripts - NASDAQ Seeking View ADRU Breaking News & Analysis - Seeking Alpha
Spotlight View ADRU Annual Report - CompanySpotlight.com OTC Report View ADRU OTC Short Report - OTCShortReport.com
TradeKing View ADRU Fundamentals - TradeKing Charts View ADRU SEC Filings - Bar Chart
WSJ View Historical Prices for ADRU - The WSJ Morningstar View Performance/Total Return for ADRU - Morningstar
MarketWatch View the Analyst Estimates for ADRU - MarketWatch CNBC View the Earnings History for ADRU - CNBC
StockMarketWatch View the ADRU Earnings - StockMarketWatch MacroAxis View ADRU Buy or Sell Recommendations - MacroAxis
Bullish View the ADRU Bullish Patterns - American Bulls Short Pains View ADRU Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ADRU Stock Mentions - StockTwits PennyStocks View ADRU Stock Mentions - PennyStockTweets
Twitter View ADRU Stock Mentions - Twitter Invest Hub View ADRU Investment Forum News - Investor Hub
Yahoo View ADRU Stock Mentions - Yahoo! Message Board Seeking Alpha View ADRU Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ADRU - SECform4.com Insider Cow View Insider Transactions for ADRU - Insider Cow
CNBC View ADRU Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ADRU - OTC Markets
Yahoo View Insider Transactions for ADRU - Yahoo! Finance NASDAQ View Institutional Holdings for ADRU - NASDAQ


Stock Charts

FinViz View ADRU Stock Insight & Charts - FinViz.com StockCharts View ADRU Investment Charts - StockCharts.com
BarChart View ADRU Stock Overview & Charts - BarChart Trading View View ADRU User Generated Charts - Trading View




Latest Financial News for ADRU


What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2
Posted on Tuesday August 14, 2018

GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products. In the second quarter, the segment’s revenue grew 3% YoY (year-over-year) at constant exchange rates to ~1.8 billion British pounds, as shown in the chart below. GlaxoSmithKline bought out Novartis’s (NVS) stake in the companies’ consumer healthcare joint venture on June 1.


Novartis’s Key Developments in July
Posted on Tuesday July 24, 2018

As we’ve already seen, Novartis (NVS) reported a 7% growth in operating revenues to ~$13.16 billion in Q2 2018. That compares to revenues of ~$12.24 billion in Q2 2017.


A Short Guide to the Novartis-AveXis Deal
Posted on Monday June 04, 2018

On May 15, leading pharmaceutical company Novartis (NVS) acquired AveXis, a US-based clinical-stage gene therapy company. This transaction strengthens Novartis’s position as a leader in gene therapy and neuroscience. The chart below summarizes the deal.


Analysts’ Recommendations for AstraZeneca as of May 15
Posted on Wednesday May 16, 2018

Analysts expect AstraZeneca (AZN) to report EPS (earnings per share) of $0.60 on revenue of $5.3 billion in the first quarter, a 2.3% fall compared to its revenue of $5.4 billion during the first quarter of 2017. AstraZeneca’s stock price has risen nearly 7.1% over the last 12 months and ~4.9% year-to-date.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.